Bispecific T-cell engager (BiTE) antibody construct blinatumomab for the treatment of patients with relapsed/refractory non-hodgkin lymphoma: final results from a phase I study - Goebeler, Maria-Elisabeth; Nagorsen, Dirk (Journal of clinical oncology, 2016)
Gesehen am 05.11.2019